Literature DB >> 34344929

Evolution of NETosis markers and DAMPs have prognostic value in critically ill COVID-19 patients.

Robert Frithiof1, Gerry A F Nicolaes2, Joram Huckriede3, Sara Bülow Anderberg1, Albert Morales4, Femke de Vries3, Michael Hultström1,5, Anders Bergqvist6, José T Ortiz-Pérez7, Jan Willem Sels8,9, Kanin Wichapong3, Miklos Lipcsey1,10, Marcel van de Poll8,11, Anders Larsson12, Tomas Luther1, Chris Reutelingsperger3, Pablo Garcia de Frutos13.   

Abstract

Coronavirus disease 19 (COVID-19) presents with disease severities of varying degree. In its most severe form, infection may lead to respiratory failure and multi-organ dysfunction. Here we study the levels and evolution of the damage associated molecular patterns (DAMPS) cell free DNA (cfDNA), extracellular histone H3 (H3) and neutrophil elastase (NE), and the immune modulators GAS6 and AXL in relation to clinical parameters, ICU scoring systems and mortality in patients (n = 100) with severe COVID-19. cfDNA, H3, NE, GAS6 and AXL were increased in COVID-19 patients compared to controls. These measures associated with occurrence of clinical events and intensive care unit acquired weakness (ICUAW). cfDNA and GAS6 decreased in time in patients surviving to 30 days post ICU admission. A decrease of 27.2 ng/mL cfDNA during ICU stay associated with patient survival, whereas levels of GAS6 decreasing more than 4.0 ng/mL associated with survival. The presence of H3 in plasma was a common feature of COVID-19 patients, detected in 38% of the patients at ICU admission. NETosis markers cfDNA, H3 and NE correlated well with parameters of tissue damage and neutrophil counts. Furthermore, cfDNA correlated with lowest p/f ratio and a lowering in cfDNA was observed in patients with ventilator-free days.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34344929     DOI: 10.1038/s41598-021-95209-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  53 in total

1.  Neutrophil extracellular traps kill bacteria.

Authors:  Volker Brinkmann; Ulrike Reichard; Christian Goosmann; Beatrix Fauler; Yvonne Uhlemann; David S Weiss; Yvette Weinrauch; Arturo Zychlinsky
Journal:  Science       Date:  2004-03-05       Impact factor: 47.728

2.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Authors:  Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

3.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.

Authors:  Graziano Onder; Giovanni Rezza; Silvio Brusaferro
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

Review 4.  How I treat disseminated intravascular coagulation.

Authors:  Marcel Levi; Marie Scully
Journal:  Blood       Date:  2017-12-18       Impact factor: 22.113

5.  SARS-CoV-2: a storm is raging.

Authors:  Savannah F Pedersen; Ya-Chi Ho
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

6.  Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review.

Authors:  Nazar Zaki; Hany Alashwal; Sahar Ibrahim
Journal:  Diabetes Metab Syndr       Date:  2020-07-08

7.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

8.  Cardiovascular comorbidity and its impact on patients with COVID-19.

Authors:  Wei-Jie Guan; Wen-Hua Liang; Jian-Xing He; Nan-Shan Zhong
Journal:  Eur Respir J       Date:  2020-06-11       Impact factor: 16.671

Review 9.  COVID-19: A collision of complement, coagulation and inflammatory pathways.

Authors:  Anoop J Chauhan; Laura J Wiffen; Thomas P Brown
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 16.036

10.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

View more
  15 in total

1.  Casting a wide NET: an update on uncontrolled NETosis in response to COVID-19 infection.

Authors:  Erin B Taylor
Journal:  Clin Sci (Lond)       Date:  2022-07-15       Impact factor: 6.876

2.  Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19.

Authors:  Ivan Vlasov; Alexandra Panteleeva; Tatiana Usenko; Mikhael Nikolaev; Artem Izumchenko; Elena Gavrilova; Irina Shlyk; Valentina Miroshnikova; Maria Shadrina; Yurii Polushin; Sofya Pchelina; Petr Slonimsky
Journal:  Cells       Date:  2021-12-10       Impact factor: 6.600

3.  Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections.

Authors:  Silke Huber; Mariam Massri; Marco Grasse; Verena Fleischer; Sára Kellnerová; Verena Harpf; Ludwig Knabl; Ludwig Knabl; Tatjana Heiner; Moritz Kummann; Magdalena Neurauter; Günter Rambach; Cornelia Speth; Reinhard Würzner
Journal:  Viruses       Date:  2021-11-26       Impact factor: 5.048

Review 4.  Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.

Authors:  Diana A Gorog; Robert F Storey; Paul A Gurbel; Udaya S Tantry; Jeffrey S Berger; Mark Y Chan; Daniel Duerschmied; Susan S Smyth; William A E Parker; Ramzi A Ajjan; Gemma Vilahur; Lina Badimon; Jurrien M Ten Berg; Hugo Ten Cate; Flora Peyvandi; Taia T Wang; Richard C Becker
Journal:  Nat Rev Cardiol       Date:  2022-01-13       Impact factor: 49.421

5.  RNA Sequencing in COVID-19 patients identifies neutrophil activation biomarkers as a promising diagnostic platform for infections.

Authors:  Richard Wargodsky; Philip Dela Cruz; John LaFleur; David Yamane; Justin Sungmin Kim; Ivy Benjenk; Eric Heinz; Obinna Ome Irondi; Katherine Farrar; Ian Toma; Tristan Jordan; Jennifer Goldman; Timothy A McCaffrey
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

Review 6.  Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management.

Authors:  Robert Stawski; Dariusz Nowak; Ewelina Perdas
Journal:  Viruses       Date:  2022-02-04       Impact factor: 5.048

7.  Plasma gp96 is a Novel Predictive Biomarker for Severe COVID-19.

Authors:  Rongguo Wei; Biyan Zhou; Shaohua Li; Debin Zhong; Boan Li; Jianqiu Qin; Liping Zhao; Lixian Qin; Jun Hu; Jiuru Wang; Shixiong Yang; Jingming Zhao; Songdong Meng
Journal:  Microbiol Spectr       Date:  2021-11-24

Review 8.  NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond.

Authors:  Yuanfeng Zhu; Xiaoli Chen; Xin Liu
Journal:  Front Immunol       Date:  2022-03-02       Impact factor: 7.561

9.  Do Circulating Histones Represent the Missing Link among COVID-19 Infection and Multiorgan Injuries, Microvascular Coagulopathy and Systemic Hyperinflammation?

Authors:  Daniela Ligi; Rosanna Maniscalco; Mario Plebani; Giuseppe Lippi; Ferdinando Mannello
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

10.  Plasma Leptin Is Increased in Intensive Care Patients with COVID-19-An Investigation Performed in the PronMed-Cohort.

Authors:  Anders Larsson; Miklós Lipcsey; Michael Hultström; Robert Frithiof; Mats Eriksson
Journal:  Biomedicines       Date:  2021-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.